Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
Abstract
7509 Background: KLN-1010 is a modified lentiviral vector generating a novel, fully human anti-BCMA CAR-T cell in vivo when administered intravenously without preparative chemotherapy to pts with RRMM. Here, we report updated findings from inMMyCAR, the first sponsored, multicenter study of an in vivo CAR-T therapy for pts with RRMM. Methods: Eligibility required RRMM with measurable disease, adequate end-organ and bone marrow (BM) function, and ≥3 prior lines of therapy, including a proteosome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Results: To date, 6 pts were infused across two dose levels (6×10 6 and 2×10 7 IU/kg). Pts ranged in age from 61-72 and had received 3-5 prior lines of therapy. 5 pts had high-risk cytogenetics. BM plasma cell involvement ranged from
Fields of Study & Subjects
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Monoclonal and Polyclonal Antibodies Research
Publication details
- Journal / source
- Journal of Clinical Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Volume
- 44
- Issue
- 16_suppl
- Pages
- 7509–7509
- Publication date
- 28 May 2026
- Language
- EN